Aqua Medical Names Bob Haggerty CEO to Take on Type 2 Diabetes
The MedTech veteran who scaled 1RF ablation for Barrett’s Esophagus into a $40 million business takes the helm as Aqua treats its first patient in the U.S. pilot study of PIMA for type 2 diabetes. PLEASANTON, Calif., Aug. 4, 2026 /PRNewswire/ — Aqua Medical, Inc., a clinical-stage medical device company developing minimally invasive endoscopic therapies for type […]
Aqua Medical Treats First U.S. Patient for Type 2 Diabetes at UNC Health Using Investigational Through-The-Scope Endoscopic Therapy
PLEASANTON, Calif., July 28, 2026 /PRNewswire/ — Aqua Medical, Inc., a clinical-stage medical technology company pioneering Endoscopic Metabolic Restoration, today announced the successful treatment of the first U.S. patient in its U.S. Food and Drug Administration (FDA)-authorized Investigational Device Exemption (IDE) clinical trial evaluating the company’s proprietary Proximal Intestinal Mucosal Ablation (PIMA) procedure for the treatment of type 2 diabetes. The landmark […]
MASS DEVICE Feature Article on Aqua Medical’s First T2D IDE Trial Patient
Aqua Medical says it has successfully treated the first type 2 diabetes patient with its proximal intestinal mucosal ablation (PIMA) procedure in an FDA investigational device exemption (IDE) trial. The clinical-stage medtech developer uses radiofrequency vapor ablation (RFVA) through a standard endoscope without fluoroscopy for the minimally-invasive, outpatient PIMA procedure in the duodenum. The FDA […]
Aqua Medical Highlights 100% Insulin Elimination for 12 Months in Patients with Type 2 Diabetes with its Breakthrough “Through-the-Scope” Procedure at Digestive Disease Week® (DDW) 2026
PLEASANTON, Calif., May 5, 2026 /PRNewswire/ — Aqua Medical, Inc., a pioneer in Endoscopic Metabolic Restoration (www.aquaendoscopy.com), yesterday announced the presentation of 12-month follow-up outside US clinical data for its proprietary radiofrequency vapor ablation (RFVA) platform at Digestive Disease Week® (DDW) 2026, highlighting the potential of its Proximal Intestinal Mucosal Ablation (PIMA) procedure to deliver durable, procedure-based treatment for type 2 diabetes. Data presented at DDW […]
The 2026 TAG Awards for MedTech Announce Winners, Honoring Innovation Across MedTech, Life Sciences, and BioTech
Charlotte, NC — APRIL 22, 2026 — The TAG Awards for MedTech, produced by The Aebli Group, is proud to announce the Class of 2026 winners, recognizing companies advancing what is possible across MedTech, Life Sciences, and BioTech. This year’s honorees were selected for solutions that demonstrate strong design, real-world relevance, market value, and the […]
Aqua Medical Secures FDA IDE to Study its Breakthrough Endoscopic Technology for the treatment of Type 2 Diabetes
PLEASANTON, Calif., Nov. 4, 2025 /PRNewswire/ — Aqua Medical, a company advancing Endoscopic Metabolic Restoration for type 2 diabetes, today announced that the U.S. Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval for its pilot clinical trial of the Proximal Intestinal Mucosal Ablation (PIMA) procedure using the company’s proprietary radiofrequency vapor ablation (RFVA) […]